Pre-test: Breakthroughs In Neuro-cognitive Disorders

16 Questions | By Isantaana | Updated: Mar 20, 2022 | Attempts: 65

Questions

Settings

Create your own Quiz

Pre-test: Breakthroughs In Neuro-cognitive Disorders - Quiz

Questions and Answers

1.

Which of the following individual cognitive assessment tools is the most sensitive in measuring cognitive dysfunction in MS?
- A.
  
  Paced Auditory Serial Addition Test (PASAT)
- B.
  
  Symbol Digit Modalities Test (SDMT)
- C.
  
  California Verbal Learning Test
- D.
  
  Brief Visuospatial Memory Test
- E.
  
  Controlled Oral Word Association Test (COWAT)
2.

Which of the following types of cognitive impairment is NOT commonly associated with CADASIL at any time point during the disease?
- A.
  
  Attention
- B.
  
  Executive dysfunction
- C.
  
  Visuospatial impairment
- D.
  
  Agnosia
- E.
  
  Reasoning
3.

Psychotic symptoms are most prevalent in which of the following dementias?
- A.
  
  Lewy body disease
- B.
  
  Alzheimer disease
- C.
  
  Frontotemporal dementia
- D.
  
  Vascular dementia
- E.
  
  Psychotic symptoms have about equal prevalence across dementias
4.

Of the following, the most troubling psychotic symptom is:
- A.
  
  Agitation
- B.
  
  Euphoria
- C.
  
  Delusion
- D.
  
  Apathy
- E.
  
  Anxiety
5.

What is the best way to differentiate Parkinson’s Disease Dementia from Dementia with Lewy Bodies?
- A.
  
  Neuroleptic sensitivity
- B.
  
  Bilateral parkinsonism
- C.
  
  Timing of onset of dementia in relation to onset of parkinsonism
- D.
  
  Presence or absence of hallucinations
6.

Which form of atypical parkinsonism is least likely to have significant cognitive deficits?
- A.
  
  Corticobasal Degeneration
- B.
  
  Progressive Supranuclear Palsy
- C.
  
  Multiple System Atrophy
- D.
  
  Dementia with Lewy bodies
7.

The clinical presentation of Chronic Traumatic Encephalopathy may include:
- A.
  
  Parkinsonian features
- B.
  
  Depression, anxiety, or poor impulse control
- C.
  
  Cerebellar signs
- D.
  
  All of the above
8.

The clinical diagnosis of Chronic Traumatic Encephalopathy:
- A.
  
  Is based on biomarker evidence of tau deposition either by PET imaging or Cerebrospinal fluid analysis
- B.
  
  Requires that the individual have more than 10 years of exposure to head trauma
- C.
  
  None of the above
9.

The following are principles of bioethics, except:
- A.
  
  Autonomy
- B.
  
  Respect for persons
- C.
  
  Beneficence
- D.
  
  Justice
10.

Mr. H visits your clinic for a diagnostic work-up related to self-reported cognitive impairment. After a full work up you conclude that he has Mild Cognitive Impairment, likely consistent with Alzheimer's disease pathology. He meets the eligibility criteria for a clinical trial for an infusion secondary prevention intervention. You have been a consultant for the pharmaceutical company sponsoring the study. Prior to enrolling Mr. H in the study which of the following should you consider:
- A.
  
  Whether the patient has capacity
- B.
  
  Whether your bias is influencing your suggestion that he enroll
- C.
  
  Whether the patient/legally authorized representative understandings the distinction between research and clinical treatment
- D.
  
  All of the above
11.

The most important useful aspect of brain volumetrics is:
- A.
  
  Accurate brain volumes
- B.
  
  Good quality MRI exams
- C.
  
  Normative data that is age/gender matched
- D.
  
  Normative data that is NOT age/gender matched
12.

True or False: Assessment of hippocampal volume loss also requires visualization of adjacent temporal horn.
- A.
  
  True
- B.
  
  False
13.

True or False: FDG-PET is helpful in differentiating AD from FTD, but not from other dementing disorders.
- A.
  
  True
- B.
  
  False
14.

True or False: Amyloid-PET can be helpful in assessing the severity of Alzheimer’s disease.
- A.
  
  True
- B.
  
  False
15.

The scientist influential in calling attention to the role of ApoE4 in Alzheimer was:
- A.
  
  Stan Prusiner
- B.
  
  Robert Katzman
- C.
  
  Allan Roses
- D.
  
  Bruno Dubois
16.

The cholinergic hypothesis of Alzheimer’s disease:
- A.
  
  Originated with David Selkoe
- B.
  
  Followed chemical and histological observations in the 1970’s
- C.
  
  Was based on the success of cholinesterase inhibitors in the 1990’s
- D.
  
  Has been replace by the amyloid hypothesis